Novo Nordisk and numerous other biopharma companies are challenging drug price negotiation provisions in the Inflation Reduction Act. Novo has filed a lawsuit claiming the act violates their First and Fifth Amendment rights. Despite their resistance, Novo and other companies have agreed to participate in the negotiation process and meet the October 1 deadline set by the Centers for Medicare & Medicaid Services (CMS). Furthermore, Novo contends that the CMS has deemed six of its insulin treatments as a singular product for price control despite the drugs having distinct formulations and separate FDA approvals. Companies such as AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, Novartis, and Merck have also filed lawsuits.
To read more, click here.
[Source: Fierce Pharma, October 2nd, 2023]